NCT03907527 - Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2019

Primary Completion Date

December 15, 2024

Study Completion Date

November 15, 2028

Conditions

Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaRefractory Fallopian Tube CarcinomaRefractory Ovarian CarcinomaRefractory Primary Peritoneal CarcinomaStage III Fallopian Tube Cancer AJCC V8Stage III Ovarian Cancer AJCC V8Stage III Primary Peritoneal Cancer AJCC V8Stage IIIA Fallopian Tube Cancer AJCC V8Stage IIIA Ovarian Cancer AJCC V8Stage IIIA Primary Peritoneal Cancer AJCC V8Stage IIIA1 Fallopian Tube Cancer AJCC V8Stage IIIA1 Ovarian Cancer AJCC V8Stage IIIA2 Fallopian Tube Cancer AJCC V8Stage IIIA2 Ovarian Cancer AJCC V8Stage IIIB Fallopian Tube Cancer AJCC V8Stage IIIB Ovarian Cancer AJCC V8Stage IIIB Primary Peritoneal Cancer AJCC V8Stage IIIC Fallopian Tube Cancer AJCC V8Stage IIIC Ovarian Cancer AJCC V8Stage IIIC Primary Peritoneal Cancer AJCC V8Stage IV Fallopian Tube Cancer AJCC V8Stage IV Ovarian Cancer AJCC V8Stage IV Primary Peritoneal Cancer AJCC V8Stage IVA Fallopian Tube Cancer AJCC V8Stage IVA Ovarian Cancer AJCC V8Stage IVA Primary Peritoneal Cancer AJCC V8Stage IVB Fallopian Tube Cancer AJCC V8Stage IVB Ovarian Cancer AJCC V8Stage IVB Primary Peritoneal Cancer AJCC V8

Interventions

BIOLOGICAL

PRGN-3005 UltraCAR-T cells

Given IP

BIOLOGICAL

PRGN-3005 UltraCAR-T cells

Given IV

Trial Locations (2)

20892

National Institutes of Health (NIH), Bethesda

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle